A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)

This is an early-phase clinical study investigating a new combination treatment, Risvutatug rezetecan (Ris-Rez) given with ivonescimab for adults with advanced solid cancers. The study aims to determine: * What dose(s) of Ris-Rez given with ivonescimab is safe and what are the side effects? * How does the body handle the drug(s)? * What dose of Ris-Rez given with ivonescimab may work best and can improve the treatment of cancer?

Trial Details

NCT ID
NCT07602855
Phase
PHASE1 / PHASE2
Sponsor
GlaxoSmithKline
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Risvutatug rezetecan
  • Ivonescimab
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Wilson, North Carolina, United States|35.72127,-77.91554
  • Canton, Ohio, United States|40.79895,-81.37845
  • Osaka, Japan|34.69379,135.50107

Key Eligibility Criteria

  • Participants are eligible to be included in the study only if all the following criteria apply:
  • Male or female participants at least 18 years of age (≥18 years) at the time of signing the informed consent form (ICF).
  • Participants with histologically confirmed advanced/metastatic solid tumors, irrespective of mutational status, as defined per cohort, as follows:
  • Histologically or cytologically confirmed SCLC (prior pathological diagnosis of complex SCLC \[such as mixed SCLC and NSCLC\] or transformed SCLC \…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →